Boyraz Gökhan, Başaran Derman, Salman Mehmet Coşkun, Özgül Nejat, Yüce Kunter
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
J Turk Ger Gynecol Assoc. 2017 Mar 15;18(1):33-37. doi: 10.4274/jtgga.2016.0190.
Previous studies reported better outcomes for transitional cell carcinoma (TCC) of the ovary when compared with more common histologic types such as serous epithelial ovarian cancers (EOCs). The aim of this study was to compare the survival outcomes of platinum- based chemotherapy in patients with stage IIIC TCCs and serous EOCs.
Clinicopathologic features and survival data of patients with FIGO stage IIIC TCC and serous EOC who had undergone primary surgery followed by six cycles of intravenous platinum/taxane between 2007 and 2015 were retrieved from the database of Hacettepe University Hospital.
We identified 14 (10.9%) TCCs and 114 (89.1%) serous EOCs. The median follow-up duration was 28 months (range, 3-101 months). Univariate analysis revealed that the TCCs and serous EOCs had similar progression-free survival (PFS) and overall survival (OS). Patients with residual disease less than 1 cm had longer OS than patients with residual disease greater than 1 cm (75.0 vs. 45.0 months, p=0.012). Cox regression analysis of all potential prognostic factors showed that the only independent prognostic factor significantly associated with OS was residual disease less than 1 cm [hazard ratio=0.38; 95% confidence interval: (0.19-0.77); p=0.007].
Surgically treated advanced stage TCCs did not have a significantly better prognosis after platinum/taxane-based chemotherapy when compared with serous EOCs. Residual tumor volume after primary surgery was the only independent predictor of OS in patients with EOC. Our results demonstrate the significance of achieving optimal cytoreduction in all histologic subtypes of EOC.
既往研究表明，与浆液性上皮性卵巢癌（EOC）等更常见的组织学类型相比，卵巢移行细胞癌（TCC）的预后更好。本研究旨在比较铂类化疗对IIIC期TCC患者和浆液性EOC患者的生存结局。
从哈杰泰佩大学医院数据库中检索2007年至2015年间接受了初次手术并随后进行六个周期静脉铂类/紫杉烷化疗的FIGO IIIC期TCC和浆液性EOC患者的临床病理特征及生存数据。
我们确定了14例（10.9%）TCC和114例（89.1%）浆液性EOC。中位随访时间为28个月（范围3 - 101个月）。单因素分析显示，TCC和浆液性EOC具有相似的无进展生存期（PFS）和总生存期（OS）。残留病灶小于1 cm的患者的OS长于残留病灶大于1 cm的患者（75.0对45.0个月，p = 0.012）。对所有潜在预后因素进行Cox回归分析显示，与OS显著相关的唯一独立预后因素是残留病灶小于1 cm [风险比 = 0.38；95%置信区间：(0.19 - 0.77)；p = 0.007]。
与浆液性EOC相比，接受手术治疗的晚期TCC在铂类/紫杉烷化疗后的预后并无显著更好。初次手术后的残留肿瘤体积是EOC患者OS的唯一独立预测因素。我们的结果证明了在EOC的所有组织学亚型中实现最佳细胞减灭术的重要性。
